Medical Oncology Unit, University of Siena, Siena, Italy.
Cancer Invest. 2012 Jan;30(1):65-71. doi: 10.3109/07357907.2011.629380.
We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev.
我们评估了肿瘤标志物 CEA 和 CA19.9 的变化，作为参与临床研究并接受化疗和贝伐珠单抗（Bev）治疗的转移性结直肠癌（mCRC）患者疾病进展的早期预测指标。72 名患者基线 CEA 或 CA19.9 血清水平较高。通过 ROC 分析，区分进展性疾病（PD）与稳定疾病（SD）/部分缓解（PR）/完全缓解（CR）的可变 CEA 截断值的曲线下面积为 0.83，区分 PD 与 SD/PR/CR 的可变 CA19.9 截断值的曲线下面积为 0.80。CEA 和 CA19.9 的升高可能预示着接受化疗和贝伐珠单抗治疗的 mCRC 患者疾病的早期进展。
